Temporal and Topographic Matrix Metalloproteinase Expression after Vascular Injury in Mice

Summary

Temporal and topographic expression of matrix metalloproteinases (MMPs) after perivascular electric injury was studied in wild-type (WT) and urokinase-deficient (u-PA^-/-) mice. Neointima formation after injury of the femoral artery was significantly reduced in u-PA^-/- mice as compared to WT mice (area of 0.002 ± 0.0007 mm² versus 0.008 ± 0.002 mm² at 3 weeks after injury; p <0.001), associated with impaired cellular migration (nuclear cell counts of 44 ± 5 versus 82 ± 9 in cross-sectional areas; p <0.001).

Zymographic and/or microscopic analysis indicated that MMP expression gradually increased to reach a maximum at 1 to 2 weeks after vascular injury. In general, MMP levels were lower in u-PA^-/- than in WT mice. In non-injured arteries, MMP-2 (gelatinase A) and MMP-3 (stromelysin-1) were produced mainly by adventitial fibroblasts and/or non-contractile smooth muscle cells (SMC). One week after injury, MMP-2 and MMP-3 levels were enhanced due to an increased number and size of producing cells; 2 to 3 weeks after injury, MMP-2 and MMP-3 were produced also by some contractile SMC, which stained with α-actin antiserum. MMP-9 (gelatinase B), MMP-12 (metalloelastase) and MMP-13 (collagenase-3) were found in macrophages located mainly in the adventitia. Immunogold electron microscopic examination revealed that MMP-2 was located predominantly in association with the cell surface of fibroblasts or SMC, while MMP-9 and MMP-12 were located in well defined storage granules within macrophages. MMP-2, MMP-3 and MMP-13, but not MMP-9 or MMP-12, were also found extracellularly, associated with elastin-containing structures (MMP-2), with the basement membrane and occasionally with collagen fibres (MMP-3), or with proteoglycans, collagen and elastin (MMP-13).

The temporal and topographic expression pattern of MMPs after vascular injury, coinciding with smooth muscle cell migration and neointima formation, thus is compatible with a role in vascular remodeling.

• References

• 1 Schwartz SM, Reidy MA, O’Brien ER. Assessment of factors important in atherosclerotic occlusion and restenosis.. Throm Haemost 1995; 74: 541-51.
• 2 Ip JH, Fuster V, Israel D, Badimon L, Badimon J, Chesebro JH. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty.. J Am Coll Cardiol 1991; 17: 77B-88B.
• 3 Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis. A special case of atherosclerosis progression.. Circulation 1992; 86 III 47-52.
• 4 Clowes AW, Reidy MA. Prevention of stenosis after vascular reconstruction: pharmacologic control of intimal hyperplasia – a review.. J Vasc Surg 1991; 13: 885-91.
• 5 Reidy MA, Jackson D, Lindner V. Neointimal proliferation: control of vascular smooth muscle cell growth.. Vasc Med Rev 1992; 3: 156-67.
• 6 Clowes AW, Clowes MM, Au YP, Reidy MA, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery.. Circ Res 1990; 67: 61-7.
• 7 Jackson CL, Reidy MA. The role of plasminogen activation in smooth muscle cell migration after arterial injury.. Ann NY Acad Sci 1992; 667: 141-50.
• 8 Reidy MA, Irvin C, Lindner V. Migration of arterial wall cells. Expression of plasminogen activators and inhibitors in injured rat arteries.. Circ Res 1996; 78: 405-14.
• 9 Southgate KM, Davies M, Booth RFG, Newby AC. Involvement of extracellular matrix degrading metalloproteinases in rabbit aortic smooth muscle cell proliferation.. Biochem J 1992; 288: 93-9.
• 10 Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat.. Circ Res 1994; 75: 539-45.
• 11 Zempo N, Kenagy RD, Au YPT, Bendeck M, Clowes MM, Reidy MA, Clowes AW. Matrix metalloproteinases of vascular cells are increased in balloon-injured rat carotid artery.. J Vasc Surg 1994; 20: 209-17.
• 12 Aoyagi M, Yamamoto M, Azuma H, Nagashima G, Niimi Y, Tamaki M, Hirakawa K, Yamamoto K. Immunolocalization of matrix metalloproteinases in rabbit carotid arteries after balloon denudation.. Histochem Cell Biol 1998; 109: 97-102.
• 13 Webb KE, Henney AM, Anglin S, Humphries SE, McEwan JR. Expression of matrix metalloproteinases and their inhibitor TIMP-1 in the rat carotid artery after balloon injury.. Arterioscler Thromb Vasc Biol 1997; 17: 1837-44.
• 14 Kenagy RD, Hart CE, Stetler-Stevenson WG, Clowes AW. Primate smooth muscle cell migration from aortic explants is mediated by endogenous platelet-derived growth factor and basic fibroblast growth factor acting through matrix metalloproteinases 2 and 9.. Circulation 1997; 96: 3555-60.
• 15 Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis.. Blood 1991; 78: 3114-24.
• 16 Vassalli JD. The urokinase receptor.. Fibrinolysis 1994; 8 (Suppl. 01) Suppl. 172-81.
• 17 Danø K, Behrendt N, Brünner N, Ellis V, Ploug M, Pyke C. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion.. Fibrinolysis 1994; 8 (Suppl. 01) Suppl. 189-203.
• 18 Eeckhout Y, Vaes G. Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin B, plasmin and kallikrein, and spontaneous activation.. Biochem J 1977; 166: 21-31.
• 19 Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix.. Curr Opinion in Cell Biol 1995; 7: 728-35.
• 20 Murphy G, Cockett I M, Stephens PE, Smith BJ, Docherty AJ. Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes.. Biochem J 1987; 248: 265-8.
• 21 Suzuki K, Enghild JJ, Morodomi T, Salvesen G, Nagase H. Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin).. Biochemistry 1990; 29: 10261-70.
• 22 Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9.. J Biol Chem 1992; 267: 3581-4.
• 23 Okada Y, Gonoji Y, Naka K, Tomita K, Nakanishi I, Iwata K, Yamashita K, Hayakawa T. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties.. J Biol Chem 1992; 267: 21712-9.
• 24 Imai K, Yokohama Y, Nakanishi I, Ohuchi E, Fujii Y, Nakai N, Okada Y. Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties.. J Biol Chem 1995; 270: 6691-7.
• 25 Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumour cells.. Nature 1994; 370: 61-5.
• 26 Carmeliet P, Moons L, Stassen JM, Van Vlaenderen I, Declercq C, Kockx M, Collen D. Vascular wound healing and neointima formation induced by perivascular injury in mice.. Am J Pathol 1997; 150: 761-6.
• 27 Carmeliet P, Moons L, Ploplis V, Plow E, Collen D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene.. J Clin Invest 1997; 99: 200-8.
• 28 Carmeliet P, Moons L, Herbert J-M, Crawley J, Lupo F, Lijnen HR, Collen D. Urokinase-type but not tissue-type plasminogen activator mediates arterial neointima formation in mice.. Circ Res 1997; 81: 829-39.
• 29 Lijnen HR, Van Hoef B, Lupu F, Moons L, Carmeliet P, Collen D. Function of plasminogen/plasmin and matrix metalloproteinase system after vascular injury in mice with targeted inactivation of fibrinolytic system genes.. Arterioscler Thromb Vasc Biol 1998; 18: 1035-45.
• 30 Carmeliet P, Moons L, Lijnen HR, Baes M, Lemaître V, Tipping P, Drew A, Eeckhout Y, Shapiro S, Lupu F, Collen D. Urokinase-generated plasmin is a candidate activator of matrix metalloproteinases during atherosclerotic aneurysm formation.. Nature Genet 1997; 17: 439-44.
• 31 Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice.. Nature 1994; 368: 419-24.
• 32 Giles AR. Guidelines for the use of animals in biomedical research.. Thromb Haemost 1987; 58: 1078-84.
• 33 Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymer-ized substrates.. Anal Biochem 1980; 102:: 196-202.
• 34 Kleiner DE, Stetler Stevenson WG.. Quantitative zymography: detection of picogram quantities of gelatinases.. Anal Biochem 1994; 218: 325-9.
• 35 Delaissé JM, Eeckhout Y, Neff L, François-Gillet C, Henriet P, Su Y, Vaes G, Baron R. (Pro)collagenase (matrix metalloproteinase-1) is present in rodent osteoclasts and in the underlying bone-resorbing compartments.. J Cell Sci 1993; 106: 1071-82.
• 36 Lupu F, Heim DA, Bachmann F, Hurni M, Kakkar VV, Kruithof EK. Plasminogen activator expression in human atherosclerotic lesions.. Arterioscler Thromb Vasc Biol 1995; 15: 1444-55.
• 37 Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EK. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries.. Arterioscler Thromb 1993; 13: 1090-100.
• 38 Hasenstab D, Forough R, Clowes AW. Plasminogen activator inhibitor type 1 and tissue inhibitor of metalloproteinases-2 increase after arterial injury in rats.. Circ Res 1997; 80: 490-6.
• 39 Jackson CL, Raines EW, Ross R, Reidy MA. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury.. Arterioscler Thromb 1993; 13: 1218-26.
• 40 Zempo N, Koyama N, Kenagy RD, Lea HJ, Clowes AW. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor.. Arterioscler Thromb Vasc Biol 1996; 16: 28-33.
• 41 Forough R, Koyama N, Hasenstab D, Lea H, Clowes M, Nikkari ST, Clowes AW. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo.. Circ Res 1996; 79: 812-20.
• 42 Kenagy RD, Vergel S, Mattsson E, Bendeck M, Reidy MA, Clowes AW. The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration.. Arterioscler Thromb Vasc Biol 1996; 16: 1373-82.
• 43 Lee E, Vaughan DE, Parikh SH, Grodzinsky AJ, Libby P, Lark MW, Lee RT. Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells.. Circ Res 1996; 78: 44-9.
• 44 Okada A, Tomasetto C, Lutz Y, Bellocq JP, Rio MC, Basset P. Expression of matrix metalloproteinases during rat skin wound healing: evidence that membrane type-1 matrix metalloproteinase is a stromal activator of pro-gelatinase A.. J Cell Biol 1997; 137: 67-77.
• 45 Shofuda K, Yasumitsu H, Nishihashi A, Miki K, Miyazaki K. Expression of three membrane-type matrix metalloproteinases (MT-MMPs) in rat vascular smooth muscle cells and characterization of MT3-MMPs with and without transmembrane domain.. J Biol Chem 1997; 272: 9749-54.
• 46 Cottam DW, Corbitt RH, Gomez DE, Rees RC, Thorgeirsson UP. Alterations in endothelial cell proteinase and inhibitor polarized secretion following treatment with interleukin-1, phorbol ester, and human melanoma cell conditioned medium.. J Cell Biochem 1996; 60: 148-60.
• 47 Padgett LC, Lui GM, Werb Z, LaVail MM. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 in the retinal pigment epithelium and interphotoreceptor matrix: vectorial secretion and regulation.. Exp Eye Res 1997; 64: 927-38.